Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenetic Biosciences (XBIO) Share-based Compensation (2023 - 2025)

Xenetic Biosciences (XBIO) has disclosed Share-based Compensation for 3 consecutive years, with $15855.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Share-based Compensation fell 42.42% year-over-year to $15855.0, compared with a TTM value of $75897.0 through Sep 2025, down 65.7%, and an annual FY2024 reading of $171814.0, down 39.31% over the prior year.
  • Share-based Compensation was $15855.0 for Q3 2025 at Xenetic Biosciences, up from $15683.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $77074.0 in Q1 2024 and bottomed at $15683.0 in Q2 2025.
  • Average Share-based Compensation over 3 years is $45971.6, with a median of $42096.0 recorded in 2024.
  • The sharpest move saw Share-based Compensation increased 11.94% in 2024, then tumbled 75.02% in 2025.
  • Year by year, Share-based Compensation stood at $74578.0 in 2023, then plummeted by 66.33% to $25108.0 in 2024, then tumbled by 36.85% to $15855.0 in 2025.
  • Business Quant data shows Share-based Compensation for XBIO at $15855.0 in Q3 2025, $15683.0 in Q2 2025, and $19251.0 in Q1 2025.